USFDA completes Pre-Approval Inspection at FTO-11 plant; Form 483 with two observations issued
USFDA completed a Pre-Approval Inspection (PAI) at the company's FTO-11 facility in Pydibhimavaram, Andhra Pradesh.
- Facility
- FTO-11 facility in Pydibhimavaram, Andhra Pradesh
- Inspection dates
- October 5, 2026 to October 7, 2026
- Inspection outcome
- Form 483 with two observations
What the company told the exchanges
The United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection (PAI) at the company's FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. The inspection was conducted from October 5, 2026 to October 7, 2026. The company has been issued a Form 483 with two observations. The company states that it will address the observations within the stipulated timeline.
What a Form 483 is
- A Form 483 is the form USFDA investigators use to record observations made during an inspection of a facility.
- It lists conditions the investigator believes may indicate deviations from applicable requirements.
- It is issued at the close of an inspection, and the company is expected to respond to the observations.
- A Pre-Approval Inspection is an inspection tied to a product approval application linked to the site.
What to note in the numbers
- The facility involved is the FTO-11 plant at Pydibhimavaram, Andhra Pradesh.
- The number of observations recorded is two.
What the company said about next steps
The company said the observations will be addressed within the stipulated timeline.
How a reader can place this
- This is a disclosure of the outcome of a regulatory inspection at one manufacturing site.
- The company's stated position is that it will respond to the observations within the timeline set for it.
Also from Dr Reddys Laboratories
Q2FY27 results on October 23rd, 2026; earnings call same day at 19:30 PM IST / 10:00 AM ET
7 Oct 2026
US IRS levies $32,350.20 penalty on step-down subsidiary over tax payment misclassification
3 Oct 2026
More numbers
- Observations in the Form 483 issued after the USFDA inspectiontwo observations
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.